This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Takizawa, T Articles by Owen, K Search for Related Content PubMed PubMed Citation Articles by Takizawa, T Articles by Owen, K Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Joint Disorders Social Bookmarking                         What's this?

A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats

Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan

K Hasimoto

Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan

N Itoh

Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan

S Yamashita

Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan

K Owen

GlaxoWellcome Research & Development, Hertfordshire, UK

1 Grepafloxacin is a new oral fluoroquinolone with potent activity against community acquired respiratory pathogens, including Streptococcus pneumoniae, and pharmacokinetic properties which allow once daily dosing. As part of its safety evaluation a study of 4 weeks duration was performed to compare the toxicity of grepafloxacin with that of a number of commercially available quinolones in the rat.

2 Groups of eight male Sprague-Dawley rats received either control material or grepafloxacin, enoxacin, lomefloxacin, ofloxacin or ciprofloxacin at an oral dosage of 300 mg/kg/day for 4 consecutive weeks.

3 Effects related to the antibacterial activity of the drugs were seen as increased caecal weight, decreased urinary excretion of sodium, increased water consumption, decreased urine volume, increased urine osmolality, soft stools and suppressed body weight gain.

4 It is well documented that fluoroquinolones can cause lesions in the cartilage of the major diarthrodial joints, and blister formation or erosion on the joint surface was observed in all quinolone-treated groups other than the grepafloxacin group.

5 Some quinolones, have been found to cause crystal-luria, which is often associated with secondary nephropathy in laboratory animals due to the poor solubility of quinolones under the alkaline conditions of the urine. In the present study, needle-like crystals in the urinary sediment were observed in enoxacin and ciprofloxacin treated groups only.

6 In conclusion, grepafloxacin was well tolerated and showed a low potential for joint toxicity and crystalluria compared to other quinolones.

Key Words: fluoroquinolones • grepafloxacin • toxicity • arthropathy • crystalluria • rat

Human & Experimental Toxicology, Vol. 18, No. 1, 38-45 (1999)
DOI: 10.1177/096032719901800106


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T Takizawa, K Hashimoto, T Minami, S Yamashita, and K Owen The comparative arthropathy of fluoroquinolones in dogs Human and Experimental Toxicology, June 1, 1999; 18(6): 392 - 399. [Abstract] [PDF]